Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicholas Brissey

Podiatrist, Foot & Ankle Surgery Robinson, IL Doctor of Podiatric Medicine

NPI 1801258629 CMS profile 2246267

1000 N Allen St, Robinson, IL 62454

Open in the dashboard

General payments

$16,131

162 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicholas Brissey of Robinson, IL is reported in the CMS Open Payments database as having received $16,131 across 162 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $50 3
2024 General $730 7
2023 General $1,716 19
2022 General $3,479 21
2021 General $1,643 21
2020 General $2,852 34
2019 General $5,661 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicholas Brissey
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Nicholas Brissey were reported at $50. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Nicholas Brissey Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $5,661 $389 $118–$1,406 $163
2020 $2,852 $191 $62–$691 $114
2021 $1,643 $329 $104–$1,341 $132
2022 $3,479 $419 $125–$1,611 $149
2023 $1,716 $377 $128–$1,164 $160
2024 $730 $394 $134–$1,168 $164
2025 $50 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $9,766 95 payments
  2. Arthrex, Inc. $2,495 14 payments
  3. Zimmer Biomet Holdings, Inc. $1,703 26 payments
  4. Great Lakes Orthopedics $1,374 7 payments
  5. Linvatec Corporation $225 3 payments
  6. Wright Medical Technology, Inc. $101 3 payments
  7. Integra LifeSciences Corporation $98 2 payments
  8. Zimvie Inc. $93 4 payments
  9. Paragon 28, Inc. $77 1 payment
  10. Amgen Inc. $76 1 payment
  11. Other $124 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,305 137 payments
  2. Travel and Lodging $5,626 24 payments
  3. Education $1,200 1 payment
Products named General payments · program years 2019–2025
  1. HOFFMANN Trauma & Extremeties $2,204 20 payments
  2. STAR $1,693 15 payments
  3. Trabecular Metal (TM) Ankle $1,287 11 payments
  4. HOFFMANN Trauma & Extremeties $1,071 8 payments
  5. INFINITY $610 6 payments
  6. T2 Trauma & Extremeties $606 5 payments
  7. T2 Trauma & Extremeties $574 8 payments
  8. VARIAX $560 6 payments
  9. PROSTEP $546 4 payments
  10. INFINITY ADAPTIS $495 4 payments
  11. Other $3,031 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

123

Median for Podiatry: 160

Drug cost

$1,692

Median for Podiatry: $2,368

Branded share of claims

53.7%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 31 $823
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 66 $681
Hydroxyzine Pamoate Generic 26 $188

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$30,827

Of which drugs: $76

Medicare patients

98

Average age 70

Services billed

437

64 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 63%
Depression 33%
Diabetes 27%
Chronic kidney disease 21%
Atrial fibrillation 18%
Ischemic heart disease 17%
Heart failure 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 19 100 $68
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 19 98 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

162 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record